Western Blot: CIP2A Antibody (2G10) [NB110-59722] - Analysis of CIP2A in NIH/3T3 cell lysate.
Immunocytochemistry/ Immunofluorescence: CIP2A Antibody (2G10) [NB110-59722] - CIP2A antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight ...read more
Flow Cytometry: CIP2A Antibody (2G10) [NB110-59722] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using CIP2A antibody (dark blue). Isotype control shown in orange. An antibody ...read more
Western Blot: CIP2A Antibody (2G10) [NB110-59722] - Detection of CIP2A in HeLa whole cell lysate.
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Tris-glycine, 150mM NaCl
0.05% Sodium Azide
Protein G purified
This CIP2A antibody is useful for Immunocytochemistry/Immunofluorescence and Western Blot. In ICC/IF, strong cytoplasmic staining is observed in U20s cells. In Western Blot analysis, a band is seen at ~90 kDa representing CIP2A. Use in Immunohistochemistry-Paraffin reported in scientific literature (PMID 25965834)
Read Publications using NB110-59722 in the following applications:
Human, mouse, rat and primate. Other species have not been tested.
Alternate Names for CIP2A Antibody (2G10)
Cancerous inhibitor of PP2A
Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
CIP2A - A lean, mean, oncoprotein machine The CIP2A protein was originally identified as p90, a cytoplasmic auto-antigen from the serum of a cancer patient. It was later found to inhibit protein phosphatase 2A (PP2A) activity as well as interact with c-myc. CIP2A's inhibitory activity blocks... Read full blog post.